PMID- 20008423 OWN - NLM STAT- MEDLINE DCOM- 20100204 LR - 20171116 IS - 1098-4275 (Electronic) IS - 0031-4005 (Linking) VI - 125 IP - 1 DP - 2010 Jan TI - Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. PG - e35-51 LID - 10.1542/peds.2008-1036 [doi] AB - OBJECTIVE: Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab. METHODS: This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged